Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

The study included 65,075 patients with solid tumor malignancies who underwent HER2 immunohistochemistry (IHC) testing using the Ventana PATHWAY anti-HER2/neu assay.

The VENTANA MET (SP44) RxDx Assay is now FDA approved to identify patients with NSCLC eligible for telisotuzumab vedotin.

Foundation Medicine today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing.

Foundation Medicine, Inc., a genomics company committed to transforming cancer care , today announced that it has expanded its immunohistochemistry (IHC) test offerings to include MET IHC testing ...

On May 21, Guardant Health, Inc. (NASDAQ:GH) announced adding a full suite of immunohistochemistry to its portfolio of tumor molecular profiling tests.

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS WIRE ...

Complete suite of IHC testing for key biomarkers in all solid tumors, including c-MET, now available in addition to Guardant360 Tissue multiomic profiling test PALO ALTO, Calif.--(BUSINESS ...

Deployment of MET IHC testing for NSQ NSCLC patients underscores this commitment and highlights Caris' dedication to improving patient care and outcomes.